InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition

InMed Pharmaceuticals Inc. (NASDAQ:INM), a leader in research, development, manufacturing and commercialization of rare cannabinoids, released unaudited financial results for the third quarter of the fiscal year which ended March 31, 2022.

Financial and Operational Highlights:

  • For the 9 months ended March 31, 2022, the company recorded a net loss of $10.7 million, or $0.81 per share, compared with a net loss of $6.9 million, or $1.11 per share, for the nine months ended March 31, 2021.

  • Research, development and patents expenses increased by $2.2 million for the nine months ended March 31, compared to the nine months ended March 31, 2021. 

  • The company incurred general and administrative expenses of $5.1 million for the nine months ended March 31, compared with $2.9 million for the nine months ended March 31, 2021.

  • At March 31, 2022, the company’s cash, cash equivalents and short-term investments were $5.9 million, which compares to $7.4 million at June 30, 2021. …

Full story available on Benzinga.com

More InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition